scholarly journals Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study

BMJ ◽  
2015 ◽  
Vol 350 (may19 2) ◽  
pp. h2335-h2335 ◽  
Author(s):  
A. Alperovitch ◽  
T. Kurth ◽  
M. Bertrand ◽  
M.-L. Ancelin ◽  
C. Helmer ◽  
...  
Keyword(s):  
Cohort Study ◽  
Primary Prevention ◽  
Older People ◽  
Population Based ◽  
Lipid Lowering ◽  
Vascular Events ◽  
Lipid Lowering Drugs

scholarly journals High visit-to-visit cholesterol variability predicts heart failure and adverse cardiovascular events: a population-based cohort study

2021 ◽  
Author(s):  
Jeffrey Shi Kai Chan ◽  
Danish Iltaf Satti ◽  
Yan Hiu Athena Lee ◽  
Jeremy Man Ho Hui ◽  
Teddy Tai Loy Lee ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Cohort Study ◽  
Cardiovascular Mortality ◽  
Cardiovascular Events ◽  
Population Based ◽  
Blood Cholesterol ◽  
Lipid Lowering

Background: Dyslipidaemia is associated with adverse cardiovascular outcomes. However, the long-term prognostic value of visit-to-visit cholesterol variability for the risks of heart failure (HF) is uncertain. We investigated the associations between cholesterol variability and the risk of HF and adverse cardiovascular events. Methods: This retrospective cohort study included patients attending family medicine clinics in Hong Kong during 2000-2003 with follow-up until 2019. Patients with at least three sets of blood cholesterol (low-density (LDL-C) and high-density (HDL-C) lipoprotein cholesterol) levels available at different visits were included. Patients with prior HF, myocardial infarction (MI), use of HF medications, and pregnancy were excluded. Visit-to-visit variability was calculated using standard deviation and coefficient of variation (CV). The primary outcome was HF. The secondary outcomes were cardiovascular mortality, and myocardial infarction. Results: A total of 5662 patients were included (2152 males; mean age 63.3+/-12.4 years; mean follow-up 15.3+/-4.6 years). Higher variability of HDL-C (hazard ratio (HR) for CV: 13.757 [6.261, 30.226], p<0.0001) predicted new-onset HF. Higher variability of LDL-C (HR for CV: 3.885 [1.942, 7.775], p=0.0001) and HDL-C (HR for CV: 39.118 [13.583, 112.657], p<0.0001) predicted higher risk of MI, but not cardiovascular mortality. These associations remained significant in patients without baseline usage of lipid-lowering medication(s) (N=4068), but were all insignificant in patients with baseline usage of lipid-lowering medication(s) (N=1594). Conclusion: Higher visit-to-visit cholesterol variability was varyingly associated with significantly increased long-term risks of HF and adverse cardiovascular events. Such associations may be negated by using lipid-lowering medication(s).

scholarly journals Socioeconomic Factors and All Cause and Cause-Specific Mortality among Older People in Latin America, India, and China: A Population-Based Cohort Study

PLoS Medicine ◽  
2012 ◽  
Vol 9 (2) ◽  
pp. e1001179 ◽  
Author(s):  
Cleusa P. Ferri ◽  
Daisy Acosta ◽  
Mariella Guerra ◽  
Yueqin Huang ◽  
Juan J. Llibre-Rodriguez ◽  
...  
Keyword(s):  
Latin America ◽  
Cohort Study ◽  
Older People ◽  
Socioeconomic Factors ◽  
Population Based ◽  
Specific Mortality ◽  
India And China

Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study

2013 ◽  
Vol 70 (1) ◽  
pp. 99-108 ◽  
Author(s):  
D. Macías Saint-Gerons ◽  
C. de la Fuente Honrubia ◽  
D. Montero Corominas ◽  
M. J. Gil ◽  
F. de Andrés-Trelles ◽  
...  
Keyword(s):  
Primary Prevention ◽  
Vascular Diseases ◽  
Population Based ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Population Based Study ◽  
Lowering Therapy
Sign in / Sign up

Export Citation Format

Share Document